Business Context and Reporting Period
This Form 6-K filing is submitted by Midatech Pharma PLC (not Biodexa Pharmaceuticals Plc as indicated in metadata) for the month of May 2019, with a specific filing date of May 24, 2019. The registrant is a foreign private issuer headquartered in Cardiff, United Kingdom. The filing serves to incorporate by reference a press release announcing the posting of the company's Annual Report and the Notice of its Annual General Meeting (AGM).
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. Consequently, the filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced Annual Report (Exhibit 99.1), which is not included in the input text.
Material Changes
No material changes regarding financial performance or operations are detailed in this specific document. The filing solely notifies the market of the availability of the Annual Report and the upcoming AGM.
Guidance, Outlook, and Risks
The document contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. Investors must refer to the attached Annual Report for such information.
Important Facts for Investors to Verify
- Verify the discrepancy between the metadata company name ("Biodexa Pharmaceuticals Plc") and the actual registrant name ("Midatech Pharma PLC").
- Access the Annual Report (Exhibit 99.1) to review actual financial results, as they are not present in this summary text.
- Confirm the date and location of the Annual General Meeting (AGM) as referenced in the press release.
- Note that Nicholas Robbins-Cherry, Chief Financial Officer, signed the report on behalf of the registrant.